Off-Label Use

Key facts

Status for prescribers

Generally lawful; the FDA does not regulate the practice of medicine

Manufacturer promotion

Limited to approved uses, with narrow exceptions described in FDA guidance

Medicaid and Part D coverage

Medically accepted indications, including compendia-supported uses

What is off-label use?

The FDA regulates the approval and marketing of drugs, not the practice of medicine. Once a drug is approved, a licensed clinician may prescribe it for a use the FDA has not reviewed if they judge it medically appropriate.

Off-label use is common where evidence moves faster than labeling, such as oncology, psychiatry and rare diseases. Pediatrics is a well-known example, because many drugs were never studied in children.

Off-label does not mean unapproved drug. The drug itself is approved; only the specific use, population, dose or route falls outside the label.

How off-label use is regulated

The rules fall mainly on manufacturers and payers rather than prescribers:

• Manufacturers: promoting a drug for an unapproved use can make it misbranded under the Federal Food, Drug, and Cosmetic Act, and off-label promotion has been the basis of large False Claims Act settlements.
• Scientific exchange: FDA guidance describes limited ways firms may share scientific information on unapproved uses with health care providers, such as responses to unsolicited requests.
• Public coverage: Medicaid and Medicare Part D pay only for medically accepted indications, which include off-label uses supported by specified compendia, and Medicare Part B has specific rules for off-label anticancer drug uses.
• Commercial payers: plans set their own policies and often require prior authorization for off-label use of high-cost drugs.

Why off-label use matters

Off-label use creates a gap between labeled and real-world demand:

• Demand forecasting: off-label volume can be large in some drug classes, so patient counts based only on labeled indications can understate use.
• Lifecycle signals: growing off-label use in a condition often precedes clinical trials and an efficacy supplement for a new indication.
• Compliance: commercial and medical affairs teams must separate promotion of approved uses from permitted scientific exchange.
• Data limits: pharmacy claims record the drug but usually not the reason for use, so off-label use has to be inferred from diagnosis codes in linked medical claims.